BRIEF: Burning Rock returns to revenue growth as loss narrows
Cancer screening company Burning Rock Biotech Ltd. (BNR.US) on Wednesday reported its revenue rose 0.8% in the third quarter year-on-year to 128.6 million yuan ($17.6 million), as it returned to…
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
The Singaporean company has filed for a Hong Kong IPO, hoping to wow investors with its product that can screen for gastric cancer using blood tests Key Takeaways: Mirex’s blood-based…
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
The innovative drug maker’s stock jumped more than 18% in a single day on high hopes for inclusion of its blockbuster new drug, Nefecon, in China’s national reimbursement drug list…
NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments
The Suzhou-based drug developer said it will commercialize its hair-loss product despite disappointing clinical testing results, as it shifts away from cancer drugs Key Takeaways: Kintor announced it will commercialize…
Sinking Burning Rock faces de-listing. But could privatization bid come first?
The cancer-screening products maker is in danger of being forcibly delisted due to its sinking stock price, as income from its former top revenue source tumbles amid an industry crackdown…
Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…